Galectin Therapeutics Inc (GALT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Galectin Therapeutics reported revenue of $0. Net income was -$30.8M, or -$0.48 per diluted share. Operating activities generated -$23.9M of cash, leaving -$23.9M of free cash flow. At fiscal year end, Galectin Therapeutics held $19.5M in total assets against $145.7M in total liabilities, including $17.7M of cash and equivalents.
Open the full interactive Galectin Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Galectin Therapeutics Key Stats
| Share Price | $3.69 |
|---|---|
| Market Cap | $243.1M |
| 52-Week Range | $2.08 – $6.51 |
| Shares Outstanding | 65.9 million (basic, 2026 Q2) |
Galectin Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$23.4M | -$30.2M | -$38.4M | -$38.1M | -$42.4M | -$20.1M |
| Pre-Tax Income | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| Diluted EPS | -$0.41 | -$0.52 | -$0.65 | -$0.74 | -$0.76 | -$0.48 |
Galectin Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$8.2M | -$5.5M | -$5.0M | -$9.1M |
| Diluted EPS | -$0.13 | -$0.09 | -$0.08 | -$0.14 |
Galectin Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.1M | $39.6M | $18.6M | $25.7M | $15.1M | $17.7M |
| Current Assets | $29.5M | $41.8M | $20.6M | $27.7M | $17.3M | $19.4M |
| Total Assets | $29.6M | $41.8M | $21.3M | $28.2M | $17.5M | $19.5M |
| Current Liabilities | $5.4M | $9.0M | $13.0M | $15.7M | $35.4M | $8.0M |
| Total Liabilities | $5.4M | $39.2M | $53.5M | $88.4M | $120.6M | $145.7M |
| Shareholders' Equity | $22.5M | $893,000 | -$33.9M | -$62.0M | -$104.8M | -$127.9M |
Galectin Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$20.6M | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M |
| Cash From Investing | — | $0 | $0 | $0 | $0 | $0 |
| Cash From Financing | $263,000 | $36.8M | $10.0M | $40.0M | $31.2M | $26.5M |
| Free Cash Flow | — | — | — | — | -$41.8M | -$23.9M |
Figures from Galectin Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Galectin Therapeutics financials page for every line item.
Galectin Therapeutics Company Profile
| Ticker | GALT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Norcross, Georgia |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001133416 |
Frequently Asked Questions
What was Galectin Therapeutics' revenue in fiscal 2025?
Galectin Therapeutics (GALT) reported revenue of $0 for fiscal 2025.
What is Galectin Therapeutics' annual revenue history?
Galectin Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Galectin Therapeutics' net income in fiscal 2025?
Galectin Therapeutics reported net income of -$30.8M for fiscal 2025.
What was Galectin Therapeutics' earnings per share (EPS) in fiscal 2025?
Galectin Therapeutics' diluted EPS was -$0.48 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Galectin Therapeutics generate in fiscal 2025?
Galectin Therapeutics generated -$23.9M of free cash flow in fiscal 2025.
What was Galectin Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Galectin Therapeutics reported revenue of $0.
How many shares of Galectin Therapeutics are outstanding?
Galectin Therapeutics reported a weighted average of 65.9 million basic shares outstanding in 2026 Q2.
What is Galectin Therapeutics' market cap?
Based on its latest closing price, Galectin Therapeutics (GALT) has a market capitalization of about $243.1M.
When does Galectin Therapeutics' fiscal year end?
Galectin Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Galectin Therapeutics headquartered?
Galectin Therapeutics lists its business address in Norcross, Georgia in its SEC filings.